Skip to main content

Table 4 Studies reporting comparative data

From: Real-world use of ceftolozane/tazobactam: a systematic literature review

Citation, study design, location Study design Patient/infection description Treatment groups Outcome description Outcome, % (n/N) p-value/aOR
C/T Comparator
Aminoglycoside/polymyxin comparator
Caffrey et al. 2020 [80]
Retrospective, multicenter, cohort
US
Cohort Patients had MDR PsA infections C/T (N = 57) vs. aminoglycoside/polymyxin-based (N = 155) Clinical cure - - -
Mortality, 30-day 17.5 (10/57) 18.1 (28/155) aOR: 0.78
95% CI: 0.30–2.03
Mortality, inpatient 15.8 (9/57) 27.7 (43/155) aOR: 0.39
95% CI: 0.16–0.93
Microbiological cure 31.0 (13/42) 30.6 (33/108) aOR: 0.88
95% CI: 0.35–2.21
Vena et al. 2020 [23]
Retrospective, multicenter, case–control
Italy
Case–control Patients had pneumonia or bacteremia caused by MDR or XDR PsA C/T (N = 16) vs. aminoglycoside/polymyxin-based (N = 32) Clinical cure 81.3 (13/16) 56.3 (18/32) 0.11
Mortality, 30-day 18.8 (3/16) 28.1 (9/32) 0.72
Microbiological cure - - -
Pogue et al. 2019 [27]
Retrospective, multicenter, case–control
US
Case–control Patients had an MDR or XDR PsA infection C/T (N = 100) vs. aminoglycoside/polymyxin-based (N = 100) Clinical cure 81.0 (81/100) 61.0 (61/100) 0.002
Mortality, in hospital 20.0 (20/100) 25.0 (25/100) 0.400
  Microbiological cure - - -
Other comparator
Fernández-Cruz et al. 2019 [26]
Retrospective, single center, case–control
Spain
Case–control Patients had hematological malignancies and PsA infection C/T (N = 19) vs. mixed SoC antibacterial agents (N = 38) Clinical cure, 14-day 89.5 (17/19) 71.1 (27/38) 0.183
Mortality, 30-day 5.3 (1/19) 28.9 (11/38) 0.045
Microbiological cure - - -
Mills et al. 2019 [83]
Retrospective, multicenter cohort
US
Cohort Patients had pneumonia with an MDR PsA culture C/T (N = 62) vs. mixed SoC antibacterial agents (N = 53) Clinical cure, 14-day 72.6 (45/62) 67.9 (36/53) 0.683
  Mortality 29.0 (18/62) 26.4 (14/53) 0.840
Microbiological cure - - -
  1. p-value < 0.05 indicates a significant difference are shown in bold
  2. aOR: Adjusted odds ratio; CI: Confidence interval; C/T: Ceftolozane/tazobactam; IV: Intravenous; MDR: Multidrug-resistant; PsA: Pseudomonas aeruginosa; SoC: Standard of care; US: United States; XDR: Extensively-drug-resistant